SCYNEXIS, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.48 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.08, a 41.94% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.86, a 20.78% increase year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.54, a 66.45% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.59, a 39.37% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.02, a 44.57% decline from fiscal 2024.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.84, a 1.60% decline from fiscal 2023.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.87, a 50.27% decline from fiscal 2022.
- SCYNEXIS, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.76, a 48.49% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.48 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $1.02 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $1.02 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $1.02 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $1.08 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $1.84 10-K · filed 2025-03-12 | |||
| 2024-09-30 | $1.84 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $1.86 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.86 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $1.87 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $1.87 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $1.87 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $1.54 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $3.76 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $4.15 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $4.20 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $4.59 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $7.30 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $7.36 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $7.39 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $7.57 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $8.17 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $8.39 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $8.59 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $0.86 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $1.24 10-K · filed 2020-03-11 | |||
| 2019-09-30 | $1.26 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.26 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $1.26 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $1.73 10-K · filed 2019-03-14 | |||
| 2018-09-30 | $1.75 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $1.75 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $1.76 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $2.80 10-K · filed 2019-03-14 | |||
| 2017-09-30 | $2.97 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $3.07 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $3.10 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $4.23 10-K · filed 2018-03-13 | |||
| 2015-12-31 | $8.17 10-K · filed 2017-03-13 | |||
| 2014-12-31 | $9.53 10-K · filed 2016-03-07 | |||
| 2013-12-31 | $50.39 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |